Patents by Inventor Kentaro Iwata

Kentaro Iwata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate
    Patent number: 11746109
    Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)ยท0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kentaro Iwata, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Misaki Homma, Yuya Oguro, Naohiro Taya, Lei Zhu, John Daniel Bailey, Marianne Langston, Siddhesh Dinanath Patil, Shruti Gour, Lilly Roy
  • CRYSTALLINE FORMS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE HEMIHYDRATE
    Publication number: 20230102273
    Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.
    Type: Application
    Filed: March 27, 2017
    Publication date: March 30, 2023
    Inventors: Kentaro IWATA, Masahiro MIZUNO, Kazuhiro MAEDA, Tsuneo YASUMA, Misaki HOMMA, Yuya OGURO, Naohiro TAYA, Lei ZHU, John Daniel BAILEY, Marianne LANGSTON, Siddhesh Dinanath PATIL, Shruti GOUR, Lilly ROY
  • COCRYSTAL
    Publication number: 20210115039
    Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 22, 2021
    Inventors: Kentaro IWATA, Yukihiro IKEDA
  • Cocrystal
    Patent number: 10906898
    Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: February 2, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kentaro Iwata, Yukihiro Ikeda
  • Cocrystal, production method thereof, and medicament containing cocrystal
    Patent number: 10836745
    Abstract: The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 17, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Koya Kimoto, Mitsuo Yamamoto, Masato Kitayama, Yasuhiro Sawai, Miyuki Hohokabe, Kentaro Iwata
  • Cocrystal, production method thereof, and medicament containing cocrystal
    Patent number: 10766876
    Abstract: The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 8, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Koya Kimoto, Mitsuo Yamamoto, Masato Kitayama, Yasuhiro Sawai, Miyuki Hohokabe, Kentaro Iwata
  • COCRYSTAL
    Publication number: 20200048245
    Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.
    Type: Application
    Filed: January 31, 2017
    Publication date: February 13, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Kentaro IWATA, Yukihiro IKEDA
  • COCRYSTAL, PRODUCTION METHOD THEREOF, AND MEDICAMENT CONTAINING COCRYSTAL
    Publication number: 20170183326
    Abstract: The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 29, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Koya Kimoto, Mitsuo Yamamoto, Masato Kitayama, Yasuhiro Sawai, Miyuki Hohokabe, Kentaro Iwata